The mast cell receptor MrgX2 and drug-induced anaphylaxis
Supported by:
5 July 2017
Activation of MrgX2, a GPCR expressed on mast cells, leads to degranulation and histamine release. MrgX2 binds promiscuously to basic peptides and small molecules, resulting in acute histamine-like adverse drug reactions, both in man and in mammalian species used in drug toxicology.
The goal of this webinar is to illustrate how knowledge of MrgX2 activity across a panel of mammalian species can be integrated into drug development to influence choice of compound, species model and dosing regimen. Insight into MrgX2 SAR offers clues as to its true physiological role.
KEYNOTE SPEAKER
Dr. Andrew J. Brown – Fellow at GlaxoSmithKline
Biomarkers aren’t just supporting drug discovery – they’re driving it
FREE market report
From smarter trials to faster insights, this report unpacks the science, strategy and real-world impact behind the next generation of precision therapies.
What you’ll unlock:
- How biomarkers are guiding dose selection and early efficacy decisions in complex trials
- Why multi-omics, liquid biopsy and digital tools are redefining the discovery process
- What makes lab data regulatory-ready and why alignment matters from day one
Explore how biomarkers are shaping early drug development
Access the full report – it’s free!
Dr. Brown has been involved in drug discovery for 20+ years. Andrew received a Ph.D. at the University of Edinburgh, then joined GlaxoWellcome. Currently he oversees secondary pharmacology at GSK, and consults with the UK Home Office.
SUPPORTED BY DISCOVERX
DiscoverX® is an innovative company that develops, manufactures, and commercialises reagents, complete cell-based assay kits, profiling and screening services as well as other turnkey solutions for the drug discovery, screening, and life science markets. Our biochemical and cell-based assays enable customers to improve research productivity and effectiveness of their screening, lead optimisation and SAR campaigns, thus accelerating the discovery and development of new drugs.
The rest of this content is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Related topics
Drug Development, GPCRs, Peptide Therapeutics, Toxicology
Related organisations
Eurofins Discovery
